Clinical Trial Update: Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing intravenous ferumoxytol to an oral iron regimen for treating anemia in non-dialysis-dependent chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• Feraheme (ferumoxytol)
• Oral iron supplement (ferrous iron)

Snippet

Sponsor: AMAG Pharmaceuticals, Inc. | Conditions: Anemia | Phase 3 | Status: COMPLETED